Clinical Trial Search

Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2) — 24.4; 15.6; 14.6; 9.8 Titer

Primary: Number of Seasonal Influenza A and /or B Cases by Age Group, in Panama (Using the Data Reported Via National Influenza Surveillance Program) — 448; 120; 123; 47…

Primary: Number of Subjects Boosted at Month 12 With Haemagglutinin-inhibition (HI) Antibody Concentrations Above the Cut-off Value — 178 Participants

Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42

Primary: Number of Subjects With Solicited Local Symptoms — 212; 16; 39; 3 Participants

Primary: Viral Copy Number in 30-minute Exhaled Breath Sample — 38,000; 12,000 Fine aerosol RNA copy number

Primary: Number of Participants Who Had Experienced a New Health Problem or the Worsening of an Existing Health Condition That Resulted in a Medical Consultation. — 234…

Primary: Number of Participants With Genotypic Resistance — 44; 1; 0; 2 participants

Primary: Change in Intentions to Take Antivirals for Pandemic Flu — 8.29; 8.16; 8.23; 8.35 score on a scale — p=>.05

Primary: Number of Participants Who Had Experienced a New Health Problem or the Worsening of an Existing Health Condition That Resulted in a Medical Consultation — 153 participants

Primary: Number of Laboratory-confirmed Influenza Infections — .22; .14 infections

Primary: Percent MMID — 0; 0; 20; 47 percentage of participants

Primary: MAARI Rate During the Epidemic Period (2007-2008) — 12503; 18998 Number of MAARI

Primary: Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen — 14.7; 27.9; 6.7; 13.6 Titer

Primary: Viral Confirmation — 6; 0 Participants

Primary: Mean Symptom Severity Score During the 2015-2016 Influenza Season for Symptom Domains as Assessed Using the Influenza-Patient Reported Outcome (FLU-PRO™) Questionnaire…

Primary: Percentage of Healthy Participants Reporting Mild-to-Moderate Influenza Disease (MMID) by Baseline A/Bethesda/MM2/H1N1 Hemagglutination Inhibition (HAI) Antibody…

Primary: Hospitalization — 26; 2 Participants

Primary: Number of pH1N1 Influenza Infections as Diagnosed by PCR From Mid-turbinate Swab — 2; 4 participants — p=0.685

Primary: Number of Patients With Clinical Phenotype Presenting Also a Sequential Activation of Immune/Infammatory Pathways. — 131 Participants

Primary: Time to Normalization of Respiratory Status (Primary Efficacy Population) — 7; 28 days — p=0.069

Primary: Number of PCR-confirmed Influenza Infections — 17; 3 Participants

Primary: Number of Subjects With Laboratory-confirmed Influenza Presenting With an Acute Respiratory Illness (ARI) and/or Isolated Fever — 120; 11 Participants

Primary: Solicted Adverse Events — 8; 12; 13; 14 participants

Primary: Number Subjects Who Responded to Two or Three Vaccinations of the MF59-H5N1 Influenza Vaccine — 0; 1; 0; 2 Subjects

Primary: Age Adjusted Percentage of Participants With a Physician Visit Due to Any Diagnosis Within 30 Days of the Index Date of the Confirmed Influenza A and B Cases in the…

Primary: Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Vaccine-matched Strains). — 6.7; 15.8 percentage of participants — p=<0.0001

Primary: Confirm Etiologies Among Suspected COVID-19 Cases — 151; 21; 13 Participants

Primary: Percentage of Participants Excreting Resistant Virus — 26.3; 35.3 percentage of participants — p=0.825

Primary: Primary Outcome — 26432; 19352 participants vaccinated out of all — p=<0.05